Boehringer Ingelheim to Develop Dicerna’s GalXC RNAi Candidate for NASH

 Boehringer Ingelheim to Develop Dicerna’s GalXC RNAi Candidate for NASH

Boehringer Ingelheim to Develop Dicerna’s GalXC RNAi Candidate for NASH

Shots:

  • Boehringer Ingelheim has accepted a GalXC RNAi candidate (DCR-LIV2) for advancement under the existing agreement b/w the companies for the discovery and development of novel therapies for chronic liver diseases
  • Dicerna will receive $170M as development and commercial milestones related to DCR-LIV2 and is eligible to receive royalties on net sales of the therapy
  • Boehringer Ingelheim will evaluate DCR-LIV2 for the treatment of NASH

Click here to­ read full press release/ article | Ref: Dicerna | Image: New England Real Estate Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post